PGNY Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 1.93%, SMA50 -8.23%, SMA200 -2.35%). The stock’s 14-day RSI is 48.71 (neutral), while the ATR of 0.89 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -22.61% below its high and over 23.77% above its low. Average 10-day trading volume of 1.18 million shares is below the 3-month average of 1.44 million, indicating normal recent market interest.

Wall Street analysts project EPS growth of 25.91% annually over the next five years. The latest quarter delivered EPS of $0.15. The next quarter is forecast at $0.15. Next year's EPS is expected at $22.05. Analyst sentiment is bullish. Analyst rating data shows there are 8 Strong Buy ratings, 2 Buy ratings, 6 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $35.00 to $23.00. The high target offers 90.01% upside. The low target suggests 24.86% downside. The mean target is $28.38. This offers 54.07% upside. Progyny, Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended November 06, 2025, missed forecasts by -61.54%. The prior quarter beat by 9.09%. Over the last six quarters, Apple has recorded several small beats. These include 19.44% in August 06, 2024.

Progyny, Inc. has 85.98 million shares outstanding. The public float is 79.59 million shares, elevated short interest at 11.18% of float. This equals 6.95 million shares. The short ratio is 6.22 days. Institutional investors hold 112.39% of the float. Insiders own 7.58%. TPG GP A, LLC holds 6.35 million shares, Anevski Peter has 680.25 thousand shares and Sturmer Michael E has 362.58 thousand shares. Over the past six months, insider transactions show net selling. They sold 31.86 thousand shares across 8 transactions.

Progyny, Inc. (NASDAQ:PGNY) closed at $18.42 USD, gaining $0.04 (0.22%) from the previous close of $18.38. The stock is currently mid-range between its 52-week high and low $16.10 and $28.75. With a market capitalization of about $1.51 billion, Progyny, Inc. is classified as a small-cap and shows market-like volatility (beta ~0.99). Key stats such as the average daily volume over the past year has been around 1.50 million shares, volume is running light vs its 52-week average. Headquartered in New York City, NY, Progyny, Inc. operates in the Healthcare sector and the Medical - Healthcare Information Services industry. Led by CEO David J. Schlanger, the company employs approximately 675 people and listed since October 25, 2019. Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States.

Progyny, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $5.93. This means the shares are trading above this model’s fair value.

Progyny, Inc. trades at a P/E ratio of 26.78, slightly below the S&P 500 average, with a price-to-sales ratio of 1.17 and a price-to-book ratio of 3.04 trading at moderately above to book value. The P/FCF stands at 7.98, also above market averages.

Progyny, Inc. (NASDAQ:PGNY) shares are flat -1.17% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Progyny, Inc. trading at a premium to the broader market with a P/E of 26.78. Analyst sentiment is bullish, with the majority of ratings in Overweight territory and a mean price target of $37.47, suggesting 103.42% upside. Our AI forecast model points to short-term strength (6.13% over two weeks), a medium-term rise (9.5% over three months), and a longer-term loss (-41.48% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Progyny, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 6.13%, with price expected at $19.55 by May 12, 2026, within a range of $19.02 to $20.07 3-Month Outlook: Projected rise of 9.5%, reaching $20.17 by July 27, 2026, with a range of $19.56 to $20.85. 1-Year Outlook: Projected loss of -41.48%, with price at $10.78 by April 28, 2027, within a range of $8.60 to $12.47.